Clinical trial – www.brainwork.md

18th August 2020

New evidence against fluoxetine in stroke recovery

https://www.brainwork.md/content/uploads/2020/08/Brainwork-Fluoxetine-Stroke-Recovery.jpg 5805 3875 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 18th August 2020 18th August 2020

Stroke is a very common disease that leads to disability in around half of its survivors.1 It has been believed that fluoxetine, a selective serotonin-reuptake inhibitor (SSRI), could improve neurological…

Anna Stelling, PhD
0
0

29th May 2020

Siponimod shows promising long-term efficacy in SPMS patients

https://www.brainwork.md/content/uploads/2020/05/Brainwork-LongTermEfficacy-e1590771801837.jpg 1920 1280 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 29th May 2020 2nd June 2020

While researchers are looking at the potential of stem cells in the treatment of multiple sclerosis (MS), novel, promising immune-modulating therapies are being developed. At this year’s virtual EAN Congress,…

Anna Stelling, PhD
0
0

29th May 2020

Paediatric multiple sclerosis: Adding to our knowledge

https://www.brainwork.md/content/uploads/2020/05/MPR761-KSA-Brainwork-2020-EAN-GC-V00-03-20200528_probability-marbles-e1590771823562.jpg 1920 1080 Anne Carter, MA (Cantab) Anne Carter, MA (Cantab) https://secure.gravatar.com/avatar/8a0679fc29066255ffcb2a69eacf9ee3?s=96&d=mm&r=g 29th May 2020 29th May 2020

Data suggest that between 2 and 5% of patients with multiple sclerosis (MS) are under 18 years old,1 yet there is only one approved treatment option in this population.2,3 During…

Anne Carter, MA (Cantab)
0
0

24th September 2019

Are stem cells in MS ready for prime time?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-stem-cells.jpg 2300 1535 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

Hot topics continued at ECTRIMS 2019 in Stockholm with Joachim Burman (Department of Neurology, Uppsala University Hospital, Sweden), who stepped up to the podium to discuss autologous haematopoietic stem cell transplantation (aHSCT)…

Peter Stevenson, PhD
1
0

24th September 2019

Enough evidence for vitamin D in MS?

https://www.brainwork.md/content/uploads/2019/09/Brainwork-vitamin-D.jpg 3450 2300 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 24th September 2019 26th September 2019

The role of vitamin D in the treatment of multiple sclerosis (MS) took centre stage during the first day of ECTRIMS 2019 in Stockholm, Sweden. In a ‘Hot Topic’ session,…

Peter Stevenson, PhD
0
0

9th July 2019

Treating nature with NURTURE: Interim results of nusinersen for SMA

https://www.brainwork.md/content/uploads/2019/07/Brainwork-NURTURE.jpg 3473 2300 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 9th July 2019 9th July 2019

Promising results for a disease-modifying treatment for spinal muscular atrophy (SMA) were presented at the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, last week.…

Mea Holm, PhD
0
0

9th July 2019

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

https://www.brainwork.md/content/uploads/2019/07/Brainwork-Natalizumab.jpg 3067 2300 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 9th July 2019 9th July 2019

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

Michael Furrer, PhD
0
0

4th July 2019

8-year follow-up data of alemtuzumab presented

https://www.brainwork.md/content/uploads/2019/07/follow-up-data-of-alemtuzumab-presented-image.jpg 1920 1280 Michael Furrer, PhD Michael Furrer, PhD https://secure.gravatar.com/avatar/47c43996bf9448b78126dd0c38021678?s=96&d=mm&r=g 4th July 2019 9th July 2019

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

Michael Furrer, PhD
0
0

20th June 2019

Machine-learning algorithm predicts psychosis from speech

https://www.brainwork.md/content/uploads/2019/06/Brainwork-MachineLearning.jpg 3150 2100 Peter Stevenson, PhD Peter Stevenson, PhD https://secure.gravatar.com/avatar/c5331bc85b1dc3f9749cac7354ddaaad?s=96&d=mm&r=g 20th June 2019 19th June 2019

Algorithms designed to find hidden clues within everyday language can predict those at risk of developing psychosis, a new study reports. Using machine learning, researchers from the Department of Psychology…

Peter Stevenson, PhD
0
0

30th November 2018

Gene therapy shows promise in Parkinson’s disease

https://www.brainwork.md/content/uploads/2018/11/Brainwork-ParkinsonsPromise.jpg 2100 1400 Mea Holm, PhD Mea Holm, PhD https://secure.gravatar.com/avatar/7a927c1dcef51229f6403ce27328c69e?s=96&d=mm&r=g 30th November 2018 30th November 2018

Interim results from a Phase Ib trial show that gene therapy may reduce the need for medication in patients with Parkinson’s disease refractory to levodopa. The investigational therapy is designed…

Mea Holm, PhD
0
0